Elizabeth Forminard $JNJ SEC Form 4 Insider Trading

Elizabeth Forminard has filed a total of 2 insider trades in $JNJ since 2021. Their most recent trade was a sale of 9,344 shares, made on Aug 06, 2026. Their largest trade was a sale of 9,344 shares, made on Aug 06, 2026. We estimate that they now own 32,912 shares of $JNJ, worth an estimated $8.5 million.

Insider Trading at $JNJ

There have been a total of 382 insider trades reported at $JNJ since 2021, with 2,250 shares purchased and 1.5 million shares sold. The most active insider traders in $JNJ stock have been Peter Fasolo, Thibaut Mongon, and William Hait. The most recent trade was a sale of 15,000 shares reported by Jennifer L Taubert (EVP, WWC. Innovative Medicine), made on Aug 17, 2026.

$JNJ Executives and Stock Owners with Insider Trades

• Peter Fasolo, Exec VP, Chief HR Officer

• Thibaut Mongon, Exec VP, WW Chair, Consumer

• William Hait, See Remarks

• Joseph J Wolk, Exec VP, CFO

• Joaquin Duato, CEO and Chairman of the Board

• Kathryn E Wengel, EVP, Chief GSC Officer

• John C Reed, EVP, Innovative Medicine, R&D

• Timothy Schmid, EVP, WW Chair, MedTech

• James D. Swanson, EVP, CIO

• Robert J Decker, Controller, CAO

• Robert J Decker, VP Corporate Controller

• Vanessa Broadhurst, EVP, Global Corp Affairs

• Jennifer L Taubert, EVP, WWC. Innovative Medicine

• Jennifer L Taubert, EVP, WW Chair, Pharmaceuticals

• Elizabeth Forminard, EVP, Chief Legal Officer

• Kathryn E Wengel, EVP, Chief TO and Risk Officer

• Ashley Mcevoy, EVP, WW Chair, MedTech

• James D. Swanson, See Remarks

*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.